[go: up one dir, main page]

EP2341785A1 - Composition alimentaire contenant des acides gras oméga 3 et des tcm - Google Patents

Composition alimentaire contenant des acides gras oméga 3 et des tcm

Info

Publication number
EP2341785A1
EP2341785A1 EP09749003A EP09749003A EP2341785A1 EP 2341785 A1 EP2341785 A1 EP 2341785A1 EP 09749003 A EP09749003 A EP 09749003A EP 09749003 A EP09749003 A EP 09749003A EP 2341785 A1 EP2341785 A1 EP 2341785A1
Authority
EP
European Patent Office
Prior art keywords
nutritional composition
fatty acids
composition according
omega
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09749003A
Other languages
German (de)
English (en)
Inventor
Benedict Wallner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PREOX.RS GMBH
Original Assignee
Preox-Rs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preox-Rs GmbH filed Critical Preox-Rs GmbH
Publication of EP2341785A1 publication Critical patent/EP2341785A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to a nutritional composition containing fatty acids, proteins, carbohydrates and other ingredients that can be used as a sole food for short or long-term use or as part of a diet.
  • a nutritional composition for the treatment of the metabolic syndrome is already known from EP 0 843 972 B1, which is based on the combination of so-called medium chain length fatty acids (MCT) with 8 or 10 carbon atoms with a high proportion by weight of 55-95 wt Omega-3 fatty acids in a low weight content of 5 - 25 wt .-% based.
  • MCT medium chain length fatty acids
  • Such a nutritional composition is tailored for the treatment of the metabolic syndrome, but appears unsuitable in terms of suitability as a sole food and / or for weight loss in the context of a diet.
  • the object of the present invention is therefore to propose a nutritional composition of the type mentioned at the outset, which as the sole food supplies the human body with all the necessary nutrients and energy, but at the same time activates the combustion of fatty acids in the liver and thus reduces the fat mass in the fatty tissue and leads to a reduction in blood lipids.
  • This object is achieved with a nutritional composition according to the features of claim 1.
  • the proposal according to the invention is based on building up the fatty acids of the nutritional composition according to the invention essentially from two components, wherein the first component consists of omega-3 fatty acids in a significantly high proportion of at least 25% by weight and the second component consists of medium-chain fatty acids with 8-12 carbon atoms in an amount of at most 50% by weight, the respective proportions of the components being based on the total weight of the fatty acids within the nutritional composition.
  • a health-optimal body composition consists of a minimum of fat in the fat tissue with a maximum of well-trained muscle mass. Such a condition is usually only by maximum endurance training in high-performance athletes (long-distance runners) to achieve. In untrained persons with increased fat mass (obesity, obesity), the problem is, on the one hand, that, e.g. In the context of a diet by extremely low calorie diet, although a gradual melting of the excess fat mass can be achieved, but at the same time there is a lack of muscle mass due to lack of exercise and the diet itself.
  • an uncontrolled training program leads to an increased calorie requirement of the muscles, but at the same time, carbohydrates (glucose and glycogen) and no fatty acids are burned out of the fatty tissue due to a lack of oxygen intake. Although this process then leads to improved fitness, but not to the desired health-promoting effect of a reduction of excess fat in the fat tissue.
  • the nutritional composition of the present invention By employing the nutritional composition of the present invention, this problem can be overcome.
  • the nutritional Because of the high content of omega-3 fatty acids of at least 25% by weight and up to 50% by weight of medium-chain fatty acids having 8-12 carbon atoms, the composition is a very high-fat food, for example in liquid form as a drink can also be used in pasty form eg in yoghurt, pudding, dressings and ice cream as well as sauces. Also, a dried, especially powdered dosage form is provided. Due to the high fat content, it achieves a very high saturation value, which is why the daily amount as a hypocaloric diet without feeling hungry is very well tolerated.
  • omega-3 fatty acids according to the invention to at least 25% by weight and medium-chain fatty acids having 8-12 carbon atoms to at most 50% by weight, which are also referred to as MCT, leads to maximum activation of combustion Fatty acids in the liver.
  • This activation of lipid metabolism in the liver indirectly leads to a reduction in the fat mass in adipose tissue and to a reduction in blood lipids, especially fatty acids and triglycerides in the blood.
  • Particularly effective fat burning in the liver is achieved when intake of the nutritional composition of the present invention is accompanied by activation of muscle fat burning through aerobic exercise, particularly when monitoring exercise by direct measurement of oxygen and carbon dioxide concentrations in the exhalation air the person always remains in the aerobic area and therefore additionally only fatty acids are used to obtain energy in the musculature.
  • the fatty acids of the nutritional composition according to the invention are understood to mean both those in free and in esterified form. They may be triglyceride bound or also in the form of fatty acid ethyl esters.
  • omega-3 fatty acids used in the context of the nutritional composition according to the invention are preferably eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and alpha-linolenic acid (ALA), which, depending on their availability, may be administered individually or in different mixtures can be used.
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • ALA alpha-linolenic acid
  • the nutritional composition comprises a significantly higher proportion of omega-3 fatty acids than omega-6 fatty acids, it being particularly advantageous if the fatty acids of the nutritional composition according to the invention comprise a maximum of 6.5 wt .-% of omega-6 fatty acids ,
  • a nutritional composition which is particularly suitable for the abovementioned objects has about 50-60 en.% Fatty acids, 15-25 en.% Proteins and 20-30 en.% Carbohydrates.
  • the unit En .-% denotes the theoretical proportion of the respective component in the total energy content of the nutritional composition, if a complete utilization of the energy content of the nutritional composition in the organism is assumed.
  • the dual principle underlying the nutritional composition according to the invention of a combination of a high proportion of omega-3 fatty acids and medium-chain fatty acids with 8-12 carbon atoms (MCT) are also suitable for the treatment of various indications, such as metabolic diseases, diabetes, obesity, inflammatory diseases of any kind due to the inhibition of eicosanoids, cardiovascular diseases due to the antiarrhythmic effect of eicosapentaenoic acid (EPA), performance enhancement of the brain to the child's intelligence development by high-dose administration of DHA and for dementia prevention, antipsychotic effect, antiproliferative effect in the context of a cancer diet, which may be supplemented by a number of other ingredients, the nutritional composition of the invention can be attached.
  • various indications such as metabolic diseases, diabetes, obesity, inflammatory diseases of any kind due to the inhibition of eicosanoids, cardiovascular diseases due to the antiarrhythmic effect of eicosapentaenoic acid ( EPA), performance enhancement of the brain to the child's intelligence development by high-dose administration
  • the nutritional composition of the present invention may be used as further ingredients, among others.
  • An improvement in the transport of the fatty acids into the mitochondria can be achieved by adding carnitine as a further constituent of the composition according to the invention.
  • Another possible component of the nutritional composition according to the invention is a lecithin fraction from so-called omega-3 eggs, ie a lecithin (phosphatidylcholine) fraction from the eggs of omega-3 rich fed chickens.
  • omega-3 eggs ie a lecithin (phosphatidylcholine) fraction from the eggs of omega-3 rich fed chickens.
  • omega-3 fatty acids namely ALA, EPA and DHA
  • the lecithin fraction the crude lecithin, can then be extracted from these omega-3 eggs.
  • omega-3 eggs are commercially produced by feeding.
  • omega-3 lecithin The biological advantage of omega-3 lecithin is that after ingestion in the small intestine, the same form circulates in the blood that remains in the body as omega-3 fatty acid in the longer term, namely as membrane phospholipid, which in turn is incorporated into all cell systems of the body of the central nervous system is integrated.
  • the omega-3-lecithin can also be used as the sole emulsifier. It is provided in the context of the invention to provide the lecithin (phosphatidylcholine) fraction from chicken eggs in a concentration of between 0.01 g and 20 g / 100 ml of the nutritional composition according to the invention in liquid form.
  • composition according to the invention can also be present in pulverulent consistency.
  • Vitamin E is known to consist of 8 isoforms with different biological activity, namely alpha, beta, gamma, delta-tocopherol, alpha, beta, gamma, delta-tocotrienol.
  • the tocotrienols in particular are considerably more effective than the alpha-tocopherol most commonly used so far, which is also available synthetically.
  • a tocotrienol extract is available on the market, which has a very strong antioxidant effect and acts neuroprotectively for example in Mb-Alzheimer's and stroke. Also, a cancer-inhibiting effect has already been demonstrated, as well as some studies have demonstrated a cholesterol reduction.
  • Tocotrienols can be used as the sole antioxidant for the preservation of the nutritional composition, and should be used in a concentration of 0.01-10 g / 100 ml of a liquid nutritional composition.
  • ubiquinone Another possible constituent of the nutritional composition according to the invention is ubiquinone.
  • Unbiquinone the so-called vitamin Q10
  • vitamin Q10 is an essential substance for the production of energy (electron transport) in the mitochondria of the cells.
  • ubiquinone is a very important fat-soluble antioxidant. It is also produced in humans in small quantities as a byproduct of sterol synthesis (main product cholesterol). Similar to But cholesterol is also absorbed by food. Dietary intake is considered essential for functioning in the body.
  • Ubiquinone is essential, especially for strongly energy-consuming tissues such as the heart muscle. Consequently, very low levels of heart muscle were measured in heart failure. Older studies have shown an improvement in heart failure with high-dose ubiquinone administration.
  • ubiquinone should be beneficial for brain function. Furthermore, an influence of diseases such as arteriosclerosis is described. The main problem so far with administration of ubiquinone is the extreme lipophilicity, which leads to a low absorption of less than 5% in tablet form.
  • the nutritional composition as liquid drink enables the optimal emulsion of ubiquinone and enormously increases the absorption, so that for the first time truly relevant plasma and tissue levels can be observed in humans. It is preferred to incorporate about 0.001-5 g / 100 ml of the liquid nutritional composition.
  • Another possible component of the nutritional composition according to the invention are extracts of red rice or green tea.
  • Red rice is the result of an inoculation of rice with a fungus, the moascus ruber, which produces a red color.
  • This recipe comes from traditional Chinese medicine, with the dry powder of ground red rice being used as a food preservative due to its bacteriostatic effect.
  • red rice was also given for diarrhea. It has also been shown some time ago that red rice has a cholesterol-lowering effect due to inhibitors of cholesterol synthesis (HMG-CoA reductase inhibitors, statins) produced by the fungus.
  • HMG-CoA reductase inhibitors, statins HMG-CoA reductase inhibitors, statins
  • the extract of red rice can also be used for preserving the nutritional composition according to the invention.
  • Green tea extract contains, in addition to caffeine, a number of highly effective antioxidants, eg quercetin, epigallocatechin, etc.
  • Caffeine is very important for the release of fatty acids from adipose tissue and can therefore have a positive effect on the weight reduction achievable with the nutritional composition according to the invention.
  • krill phospholipids are also possible component of the nutritional composition according to the invention.
  • the Krill liquid extract consists mainly of phospholipids, which essentially contain EPA and DHA.
  • Krill oil is therefore suitable not only as a source of omega-3 fatty acids that is particularly useful for the body, but also as part of the nutritional composition according to the invention as an emulsifier for the nutritional composition in liquid form with a high content of omega-3 fatty acids. It is proposed to add krill phospholipids to a liquid nutritional composition at a dose of 0.01-20 g / 100 ml.
  • Another possible component of the nutritional composition according to the invention are plant sterols, such as sitosterol / esters, sitostanol esters, which are already in use in the food industry as cholesterol-lowering products.
  • Plant sterols reduce cholesterol intake in the small intestine. This can be achieved a reduction of LDL cholesterol up to 15%.
  • Sitostanol / esters are preferably used in a dosage between 0.01 and 10 g / 100 ml of liquid nutritional composition.
  • cholestyramine or colestipol which act as anion exchange resins, may also be provided as a further constituent of the nutritional composition according to the invention. Since such anion exchange resins swell up with the addition of water and form a gel, they are realizable in the form of a gelatinous or paste-like administration form of the nutritional composition according to the invention, for example in the form of a yoghurt or pudding. sierbar. In the context of the invention it is envisaged to add about 0.1-10 g / 100 ml of gelatinous nutritional composition according to the invention.
  • ground plantago As a further component of the nutritional composition according to the invention, ground plantago, guar gum, dried and ground guava, mango and / or papaya fruits can be used.
  • Plantago Indian psyllium seed
  • Ground Plantago is used as a soluble and insoluble fiber to treat constipation.
  • Plantago also binds bile acids, which can lead to a 10-15% reduction in high-dose LDL cholesterol.
  • oligosaccharides By complexing oligosaccharides, Plantago also leads to a delayed carbohydrate intake and thus to an improvement in glucose tolerance.
  • the nutritional composition according to the invention is in the form of a gel or in pasty form, e.g. When yoghurt or pudding is present, pre-swollen plantago gels may be added as gelling and binding agents, with a dosage between 0.1 and 10 g / 100 ml of nutritional composition being suggested.
  • Guar gum can also be used in a similar manner, since it also has a positive effect on cholesterol levels due to bile acid binding as well as a sustained release effect on KH absorption.
  • Guava, mango and papaya fruits contain abundant soluble and insoluble fiber, which is why they can be added in a dried and ground state as a powder of the nutritional composition according to the invention in liquid or pasty form.
  • the dried fruits are also very tasty and can also function as a flavor additive. Dosages between 0.1 and 10 g / 100 ml of the nutritional composition according to the invention are conceivable.
  • Another component of the nutritional composition according to the invention is an extract from Garcinia cambogia into consideration. This South and Southeast Asian tropical fruit tastes sour, due to its high content Hydroxicititrate is caused. This substance has a clearly in vitro detectable inhibitory effect on fatty acid synthesis - carbohydrates, which is why one assumes an inhibitory effect on obesity.
  • dosages between 0.1 and 15 g / 100 ml of liquid nutritional composition appear conceivable.
  • carbohydrate which acts as a sweetener and which comprises glucose and fructose units bonded via an ⁇ , 1, 6 glucosidic bond.
  • carbohydrate is known as isomaltulose, e.g. available under the trade name Palatinose TM.
  • the aforementioned further constituents can be used both individually and in combination, depending on the indication.
  • a nutritional composition according to the invention in liquid form comprises 9.2 g fatty acid, 9.3 g carbohydrates and 7.5 g protein, the carbohydrates being formed entirely from sugar.
  • the fatty acids include 5.13 g of saturated fatty acids, 1.13 g of monounsaturated and 2.94 g of polyunsaturated fatty acids.
  • the nutritional composition '1, 0 g dietary fiber, in particular inulin and oligofructose comprises.
  • the fatty acid fraction comprises, in absolute terms, 0.48 g of EPA, 0.48 g of DHA and 1.44 g of ALA, corresponding to 26.1% by weight, based on the total weight of the fatty acids, and 4.5 g of medium-chain fatty acids having 8 to 12 carbon atoms, corresponding to 48.9% of the total weight of the fatty acids.
  • omega-6 fatty acids are contained in an amount of 0.56 g, corresponding to 6.1% by weight, and omega-9 fatty acids in an amount of 0.34 g, corresponding to 3.7% by weight.
  • the energy distribution of the nutritional composition thus formed was 20% by weight of proteins, 55% by weight of fatty acids and 25% by weight of carbohydrates.
  • the nutritional composition thus formed was prepared as a liquid drink and can be used as a sole food for continuous nutrition as well as in the context of a diet.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition alimentaire, qui contient des acides gras, des protéines, des glucides et des constituants supplémentaires. Selon l'invention, les acides gras comprennent un mélange d'acides gras à deux composant, le premier composant étant constitué d'acides gras oméga 3 en une proportion d'au moins 25 % en poids et le second composant étant constitué d'acides gras à chaînes moyennes comportant 8 à 12 atomes de carbone en une proportion d'au plus 50 % en poids, respectivement par rapport au poids total des acides gras.
EP09749003A 2008-10-29 2009-10-28 Composition alimentaire contenant des acides gras oméga 3 et des tcm Withdrawn EP2341785A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008053682 2008-10-29
PCT/EP2009/007712 WO2010049142A1 (fr) 2008-10-29 2009-10-28 Composition alimentaire contenant des acides gras oméga 3 et des tcm

Publications (1)

Publication Number Publication Date
EP2341785A1 true EP2341785A1 (fr) 2011-07-13

Family

ID=41478622

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09749003A Withdrawn EP2341785A1 (fr) 2008-10-29 2009-10-28 Composition alimentaire contenant des acides gras oméga 3 et des tcm

Country Status (6)

Country Link
US (1) US20110287145A1 (fr)
EP (1) EP2341785A1 (fr)
CA (1) CA2741352A1 (fr)
MX (1) MX2011004379A (fr)
WO (1) WO2010049142A1 (fr)
ZA (1) ZA201103915B (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843972A1 (fr) * 1996-11-20 1998-05-27 N.V. Nutricia Composition nutritionnelle comprenant des graisses pour le traitement du syndrome métabolique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) * 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
DE3903057A1 (de) * 1989-02-02 1990-08-09 Braun Melsungen Ag Fettemulsion zur endotrachealen applikation, ihre herstellung und anwendung
US5258197A (en) * 1989-09-20 1993-11-02 Nabisco, Inc. Reduced calorie triglyceride mixtures
DE19503993A1 (de) * 1995-02-08 1996-08-14 Johann Friedrich Dr Med Desaga Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6130244A (en) * 1998-02-25 2000-10-10 Abbott Laboratories Product and method to reduce stress induced immune suppression
US6180139B1 (en) * 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
US6596762B2 (en) * 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7144595B2 (en) * 2001-11-16 2006-12-05 Brandeis University Prepared foods containing triglyceride-recrystallized non-esterified phytosterols
JP5448297B2 (ja) * 2003-10-16 2014-03-19 テクコム・グループ・リミテッド・ライアビリティ・カンパニー 低減した血中応答を有する低減可消化炭水化物食物
EP1629727A1 (fr) * 2004-08-24 2006-03-01 N.V. Nutricia Composition comprenant des polysaccharides fermentescicles
US8017162B2 (en) * 2005-10-26 2011-09-13 Oryza Oil & Fat Chemical Co., Ltd. Anti-inflammatory agent
US7989009B2 (en) * 2006-02-02 2011-08-02 Advocare International, L.P. Composition and method for promoting weight loss

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0843972A1 (fr) * 1996-11-20 1998-05-27 N.V. Nutricia Composition nutritionnelle comprenant des graisses pour le traitement du syndrome métabolique

Also Published As

Publication number Publication date
MX2011004379A (es) 2011-09-26
US20110287145A1 (en) 2011-11-24
ZA201103915B (en) 2012-01-25
WO2010049142A1 (fr) 2010-05-06
CA2741352A1 (fr) 2010-05-06

Similar Documents

Publication Publication Date Title
AT407821B (de) Mittel auf der basis von naturstoffen
DE69122099T2 (de) Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
DE60215156T3 (de) Säurereguliertes viskoses ballaststoffsystem und seine verwendung
DE3873800T2 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
DE60118019T2 (de) Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung
DE60207877T2 (de) Zusammensetzung enthaltend Procyanidine zur Verminderung des Appetits bei Säugetieren
DE10109798A1 (de) Gesundheitsfördernde Zusammensetzung von Verbindungen
JP2016199536A (ja) 筋肉増強およびメタボリックシンドローム改善ならびにｑｏｌ改善のための組成物
EP2976091B1 (fr) Composition à action antioxydante et utilisation de ladite composition
DE69823661T2 (de) Funktionelle lebensmittelzubereitung
WO2019011955A2 (fr) Solubilisat contenant de la curcumine et optionnellement au moins une autre substance active
KR20080105023A (ko) 근육 소모의 치료를 위한 기능성식품 조성물
Kosmala et al. The effects of strawberry, black currant, and chokeberry extracts in a grain dietary fiber matrix on intestinal fermentation in rats
EP1784201A2 (fr) Composition physiologiquement active
DE20220180U1 (de) Nahrungsergänzungsmittel
DE102011008478A1 (de) Ganzheitliches Nahrungsergänzungsmittel
EP1608387A2 (fr) COMBINAISONS DE PRINCIPES ACTIFS D'HUILES CONTENANT DES ACIDES GRAS w3 AVEC DES EXTRAITS VEGETAUX CONTENANT DES POLYPHENOLS ET UTILISATION DESDITES COMBINAISONS
DE202011105533U1 (de) Vitalstoff-Zusammensetzung gemäß asiatischer und mediterraner Ernährungskonzepte
CH717329B1 (de) Nahrungsergänzungsmittel
LU501504B1 (de) Pulverförmiges nahrungsergänzungsmittel zur herstellung eines getränks
EP2341785A1 (fr) Composition alimentaire contenant des acides gras oméga 3 et des tcm
EP4561370A1 (fr) Comprimé soluble notamment destiné à être utilisé en tant que complément alimentaire
DE10204637A1 (de) Rezeptur aus Soja-Isoflavonen und/oder Leinsamenlignanen und Nachtkerzenöl oder Gamma-Linolensäure
EP3941220B1 (fr) Complément alimentaire et aliment
LU500687B1 (de) Nahrungs- oder diätische zusammensetzung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110524

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PREOX.RS GMBH

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140828

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150108